Hemab Therapeutics shows proof‑of‑mechanism for HMB-002 in von Willebrand disease and unveils HMB-003 for heavy menstrual bleeding at ISTH 2026
Executive summary: Hemab Therapeutics presented interim clinical data for HMB-002 showing ≥2.4‑fold peak increases in VWF and FVIII and normalization of thrombin generation and APTT, and announced HMB-003 for heavy menstrual bleeding. The results provide a proof‑of‑concept for a novel factor mimetic that could address unmet needs in von Willebrand disease and expand treatment options for heavy menstrual bleeding.
Who is involved: Hemab Therapeutics (presenter), ISTH 2026 congress attendees, investigators of the HMB-002 study.
Likely next: Further clinical testing will be required to establish efficacy and safety before regulatory submission.
At the ISTH 2026 congress, Hemab Therapeutics released clinical data indicating that its investigational factor mimetic HMB-002 produced dose‑dependent increases of at least 2.4‑fold in von Willebrand factor and factor VIII, normalized thrombin generation and activated partial thromboplastin time. The company also introduced HMB-003, a new candidate targeting heavy menstrual bleeding. The data suggest a mechanistic basis for further development, though no efficacy or safety endpoints were disclosed.
Timeline
- — Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress (GlobeNewswire)
- — Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026 (PR Newswire)
Analysis — what this means
Sectors affected
- Von Willebrand factor therapeutics
Historical parallels
- FDA approval of recombinant von Willebrand factor (Vonvendi) in 2015
- EMA approval of desmopressin intranasal spray for VWD in 2002
Key entities
Sources
- Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress — GlobeNewswire
- Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026 — PR Newswire